Share on StockTwits

Orexigen Therapeutics (NASDAQ:OREX) saw unusually large options trading on Tuesday. Traders bought 1,049 put options on the company, AnalystRatingsNetwork.com reports. This is an increase of 201% compared to the typical daily volume of 349 put options.

Separately, analysts at Zacks reiterated a “neutral” rating on shares of Orexigen Therapeutics in a research note on Wednesday, July 16th. They now have a $5.50 price target on the stock. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Orexigen Therapeutics presently has an average rating of “Buy” and a consensus price target of $8.92.

Orexigen Therapeutics (NASDAQ:OREX) traded down 0.37% during mid-day trading on Tuesday, hitting $5.38. The stock had a trading volume of 1,836,778 shares. Orexigen Therapeutics has a 52 week low of $4.60 and a 52 week high of $7.82. The stock’s 50-day moving average is $5.49 and its 200-day moving average is $6.08. The company’s market cap is $659.2 million.

Orexigen Therapeutics (NASDAQ:OREX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.21) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.21). Analysts expect that Orexigen Therapeutics will post $-0.17 EPS for the current fiscal year.

Orexigen Therapeutics, Inc develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body’s efforts to compensate for weight loss.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.